Fred T Fiedorek Selected Research

muraglitazar

7/2009	Efficacy and safety of muraglitazar: a double-blind, 24-week, dose-ranging study in patients with type 2 diabetes.
4/2009	Coadministration of muraglitazar plus glyburide: improvement of glycaemic and lipid profiles in patients with type 2 diabetes.
9/2008	Improvement of glycaemic and lipid profiles with muraglitazar plus metformin in patients with type 2 diabetes: an active-control trial with glimepiride.
5/2006	Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Fred T Fiedorek Research Topics

Disease

12	Type 2 Diabetes Mellitus (MODY) 01/2022 - 09/2002
5	Weight Gain 01/2018 - 02/2004
3	Body Weight (Weight, Body) 09/2009 - 09/2002
3	Hyperglycemia 09/2009 - 05/2006
3	Heart Failure 04/2009 - 05/2006
2	Stroke (Strokes) 05/2010 - 05/2006
2	Coronary Disease (Coronary Heart Disease) 05/2010 - 09/2002
2	Edema (Dropsy) 05/2006 - 02/2004
2	Hypoglycemia (Reactive Hypoglycemia) 02/2004 - 09/2002
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2022
1	Anorexia Nervosa 01/2018
1	Vomiting 11/2017
1	Gastroparesis 11/2017
1	Hypercholesterolemia 05/2010
1	Infections 09/2009
1	Weight Loss (Weight Reduction) 04/2009
1	Pancreatic Neoplasms (Pancreatic Cancer) 05/2006
1	Sudden Death 05/2006
1	Duodenal Ulcer (Curling's Ulcer) 05/2006
1	Insulin Resistance 11/2004
1	Dyslipidemias (Dyslipidemia) 09/2002

Drug/Important Bio-Agent (IBA)

5	LipidsIBA 07/2009 - 09/2002
4	Glucose (Dextrose)FDA LinkGeneric 09/2009 - 09/2002
4	muraglitazarIBA 07/2009 - 05/2006
3	Insulin (Novolin)FDA Link 09/2009 - 11/2004
3	Glucovance FDA LinkGeneric 02/2004 - 09/2002
3	TabletsIBA 02/2004 - 09/2002
2	relamorelinIBA 01/2018 - 11/2017
2	Pharmaceutical PreparationsIBA 05/2010 - 07/2009
2	Hypoglycemic Agents (Hypoglycemics)IBA 09/2009 - 09/2002
2	dapagliflozinIBA 09/2009 - 04/2009
2	Pioglitazone (Actos)FDA Link 07/2009 - 05/2006
2	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 04/2009 - 05/2006
2	Triglycerides (Triacylglycerol)IBA 09/2008 - 05/2006
2	Metformin (Glucophage)FDA LinkGeneric 09/2008 - 05/2006
2	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 02/2004 - 09/2002
1	Exenatide (Byetta)FDA Link 01/2022
1	Hormones (Hormone)IBA 01/2018
1	GhrelinIBA 01/2018
1	saxagliptin FDA Link 05/2010
1	SodiumIBA 04/2009
1	Glyburide (Glibenclamide)FDA LinkGeneric 04/2009
1	Sodium-Glucose Transport ProteinsIBA 04/2009
1	glimepiride (Amarel)FDA LinkGeneric 09/2008
1	HDL CholesterolIBA 05/2006
1	HIV Protease InhibitorsIBA 11/2004
1	Lopinavir FDA Link 11/2004
1	Ritonavir (Norvir)FDA Link 11/2004
1	Atazanavir Sulfate (Reyataz)FDA Link 11/2004
1	Rosiglitazone (Avandia)FDA Link 02/2004
1	Blood Glucose (Blood Sugar)IBA 09/2002

Therapy/Procedure

4	Glycemic Control 05/2006 - 09/2002
1	Subcutaneous Infusions 01/2022
1	Therapeutics 11/2004